Using PROTACs for targeted protein degradation in drug discovery

AMSBIO has introduced a new range of homogeneous proximity assays, critical enzymes and small molecule inhibitors to assess the chemical adaptor function of Proteolysis Targeting Chimeras (PROTACs).

Using PROTACs for targeted protein degradation in drug discovery

Targeted protein degradation using PROTACs is a new and promising therapeutic method in drug discovery. PROTACs have the ability to regulate protein degradation through targeted control of ubiquitin E3 ligases. This novel technology allows for the degradation of disease-related proteins and offers many advantages over traditional protein inhibition.

The PROTAC method offers many advantages compared to traditional protein inhibition. Inhibitors require sustained protein binding to evoke the intended biological reaction. This can be problematic in the incidence of target overexpression, the presence of competing ligands, or protein mutations that lead to binding resistance. The PROTAC model bypasses these issues by promoting degradation that circumvents the native resistance of proteins against sustained inhibition.

Even select weak binding and promiscuous ligands can be used with PROTACs and still demonstrate high degradation efficacy. Also, ineffectual ligands which do not modulate the cellular functions of the protein of interest can be used to mediate degradation through PROTACs. Whether the ligand is a strong inhibitor, a weak binder, promiscuous, or ineffectual, PROTACs offer the ability to degrade proteins previously believed to be 'undruggable' through conventional small molecule inhibition.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    AMS Biotechnology. (2019, July 19). Using PROTACs for targeted protein degradation in drug discovery. News-Medical. Retrieved on October 15, 2019 from https://www.news-medical.net/news/20190719/Using-PROTACs-for-targeted-protein-degradation-in-drug-discovery.aspx.

  • MLA

    AMS Biotechnology. "Using PROTACs for targeted protein degradation in drug discovery". News-Medical. 15 October 2019. <https://www.news-medical.net/news/20190719/Using-PROTACs-for-targeted-protein-degradation-in-drug-discovery.aspx>.

  • Chicago

    AMS Biotechnology. "Using PROTACs for targeted protein degradation in drug discovery". News-Medical. https://www.news-medical.net/news/20190719/Using-PROTACs-for-targeted-protein-degradation-in-drug-discovery.aspx. (accessed October 15, 2019).

  • Harvard

    AMS Biotechnology. 2019. Using PROTACs for targeted protein degradation in drug discovery. News-Medical, viewed 15 October 2019, https://www.news-medical.net/news/20190719/Using-PROTACs-for-targeted-protein-degradation-in-drug-discovery.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.
Post a new comment
Post
You might also like... ×
ScreenIn3D receives technology innovation prize